Clinical trials show tirzepatide produces greater average weight loss (22.5% vs 14.9% of body weight [1] )
As semaglutide and tirzepatide seek to expand their approved indications, e.g., potentially adding heart failure, chronic kidney disease or MASH, following several successful phase 3 trial readouts in 2023 and 2024, more pathways open up to Medicare reimbursement of AOMs within existing rules

Seek urgent medical attention (call 999 or go to A&E) if you experience: Severe or persistent vomiting, or inability to keep fluids down for more than 24 hours Severe upper abdominal pain, particularly if it radiates to the back (possible pancreatitis) Severe right-sided upper abdominal pain, with or without fever or yellowing of the skin or eyes (possible gallbladder problems a recognised class signal with GLP-1 receptor agonists) [14] [15] Contact NHS 111 or your GP if you experience: Fast, irregular heartbeat or palpitations Symptoms of hypoglycaemia (shakiness, sweating, confusion), particularly if taking insulin or other glucose-lowering medicines Dizziness or signs of dehydration (reduced urine output, dry mouth, light-headedness) If you think you have experienced a side effect from any medicine, you can report it via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or through the Yellow Card app

They can yield 1520% weight reductions in adults, previously only possible after bariatric surgery (Gross)
Transferring the solution to another container introduces a significant risk of contamination and potential adsorption to the container walls
For 2mg, draw 0.4ml (40 units)